NCT07394387 2026-02-06
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
Clinical Trials
8 trialsNCT07351487 2026-01-20
Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT07254858 2025-11-28
CISN-L
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Not yet recruiting
NCT06734533 2024-12-16
Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .
Hunan Cancer Hospital
Recruiting
NCT06308939 2024-03-13
Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT05386524 2023-02-16
Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC
Fudan University
Phase 2 Unknown
NCT05429684 2022-06-23
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown
NCT04809779 2021-03-22
NeoPD1TNBC
First Affiliated Hospital, Sun Yat-Sen University
Phase 2 Unknown